Change in Brain Metabolism and Cognitive Function by Aripiprazole

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jun Soo Kwon, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT01562808
First received: March 22, 2012
Last updated: March 23, 2012
Last verified: March 2012
  Purpose

Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.

The investigators explored the relationship between changes in brain metabolism and working memory performance.


Condition Intervention
Antipsychotics
Cognition
Brain Metabolism
Dopamine Receptor Occupancy
Drug: Aripiprazole

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Reaction time of correct response in N-back task [ Time Frame: 48 hrs after the administration of aripiprazole ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: January 2009
Study Completion Date: January 2012
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Aripiprazole
    single oral administration of aripiprazole
  Eligibility

Ages Eligible for Study:   19 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers
  • right-handed

Exclusion Criteria:

  • any significant abnormality on routine lab
  • any psychiatric disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01562808

Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Principal Investigator: Jun Soo Kwon, M.D., Ph.D. Seoul National University Hospital
  More Information

No publications provided

Responsible Party: Jun Soo Kwon, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01562808     History of Changes
Other Study ID Numbers: A070001
Study First Received: March 22, 2012
Last Updated: March 23, 2012
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on August 28, 2014